Peramivir (Synonyms: RWJ-270201; BCX-1812)

Name: Peramivir
Brand: MedChemExpress
SKU: HY-17015A
Rating: 5.0 (13 reviews)

製品番号: HY-17015A 純度: 99.94%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

Peramivir is an novel cyclopentane neuraminidase inhibitor of influenza virus. Peramivir has antiviral activity and anti-cytokines stom effects. Peramivir can be used for the research of COVID-19.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

Peramivir 構造式

CAS 番号 : 330600-85-6

容量	価格（税別）	在庫状況	数量
>無料サンプル (0.1 - 0.2 mg)		今すぐ申し込む
5 mg	$80	在庫あり	Estimated Time of Arrival: December 31
10 mg	$130	在庫あり	Estimated Time of Arrival: December 31
25 mg	$250	在庫あり	Estimated Time of Arrival: December 31
50 mg	$400	在庫あり	Estimated Time of Arrival: December 31
100 mg	$560	在庫あり	Estimated Time of Arrival: December 31
200 mg		お問い合わせ
500 mg		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 13 publication(s) in Google Scholar

Other Forms of Peramivir:

Peramivir trihydrate 在庫あり

顧客検証

•University of Glasgow. 2023.

IKK アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

IKK-α IKK-β IKK IKKε TBK1

JNK アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

JNK1 JNK2 JNK3 JNK

STAT アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

STAT3 STAT5 STAT6 STAT1

p38 MAPK アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

p38 MAPK Akt1 p38α p38β MAPK13 p38δ p38γ

ERK アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

ERK ERK1 ERK2 ERK5 ERK8

生物活性
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

IC₅₀ & Target

IKK-α

STAT3

ERK1

ERK2

Cellular Effect

Cell Line	Type	Value	Description	References
HEK293	IC₅₀	0.07 nM Compound: 5	Inhibition of oseltamivir-resistant Influenza A virus A/WSN/1933(H1N1) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured after 15 mins by fluorometric assay Inhibition of oseltamivir-resistant Influenza A virus A/WSN/1933(H1N1) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured after 15 mins by fluorometric assay	[PMID: 27167096]
HEK293	IC₅₀	0.3 nM Compound: 5	Inhibition of oseltamivir-resistant Influenza A virus A/Vietnam/1194/2004(H5N1) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured after 15 mins by fluorometric assay Inhibition of oseltamivir-resistant Influenza A virus A/Vietnam/1194/2004(H5N1) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured after 15 mins by fluorometric assay	[PMID: 27167096]
HEK293	IC₅₀	0.7 nM Compound: 5	Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured after 15 mins by fluorometric assay Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured after 15 mins by fluorometric assay	[PMID: 27167096]
HEK293	IC₅₀	0.8 nM Compound: 5	Inhibition of Influenza A virus A/Shanghai/01/2014(H7N9) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured after 15 mins by fluorometric assay Inhibition of Influenza A virus A/Shanghai/01/2014(H7N9) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured after 15 mins by fluorometric assay	[PMID: 27167096]
HEK293	IC₅₀	146 nM Compound: 5	Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant neuraminidase R292K mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured after 15 mins by fluorometric assay Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant neuraminidase R292K mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured after 15 mins by fluorometric assay	[PMID: 27167096]
HEK293	IC₅₀	225 nM Compound: 5	Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant neuraminidase E119A mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured after 15 mins by fluorometric assay Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant neuraminidase E119A mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured after 15 mins by fluorometric assay	[PMID: 27167096]
HEK293	IC₅₀	3.3 nM Compound: 5	Inhibition of oseltamivir-resistant Influenza A virus A/Vietnam/1194/2004(H5N1) recombinant neuraminidase H275Y mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured after 15 mins by fluorometric assay Inhibition of oseltamivir-resistant Influenza A virus A/Vietnam/1194/2004(H5N1) recombinant neuraminidase H275Y mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured after 15 mins by fluorometric assay	[PMID: 27167096]
HEK293	IC₅₀	3.6 nM Compound: 5	Inhibition of Influenza A virus A/WSN/1933(H1N1) recombinant neuraminidase H275Y mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured after 15 mins by fluorometric assay Inhibition of Influenza A virus A/WSN/1933(H1N1) recombinant neuraminidase H275Y mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured after 15 mins by fluorometric assay	[PMID: 27167096]
MDCK	CC₅₀	373 μM Compound: 3	Cytotoxicity against MDCK cells infected with Influenza A virus (A/WSN/33(H1N1)) after 72 hrs by CellTiter-Glo assay Cytotoxicity against MDCK cells infected with Influenza A virus (A/WSN/33(H1N1)) after 72 hrs by CellTiter-Glo assay	[PMID: 29141777]
MDCK	CC₅₀	> 100 μM Compound: Peramivir	Cytotoxicity against MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34700269]
MDCK	CC₅₀	> 101 μM Compound: Peramivir	Cytotoxicity against MDCK cells incubated for 48 hrs by MTT assay Cytotoxicity against MDCK cells incubated for 48 hrs by MTT assay	[PMID: 36521178]
MDCK	CC₅₀	> 1 x 10⁵ nM Compound: 4; PE	Cytotoxicity against MDCK cells after 48 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay Cytotoxicity against MDCK cells after 48 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay	[PMID: 29324342]
MDCK	CC₅₀	> 1 x 10⁵ nM Compound: 5	Cytotoxicity against MDCK cells after 48 hrs by CellTiter 96 AQueous Non-Radioactive cell proliferation assay Cytotoxicity against MDCK cells after 48 hrs by CellTiter 96 AQueous Non-Radioactive cell proliferation assay	[PMID: 27167096]
MDCK	CC₅₀	> 200 μM Compound: Peramivir	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31954881]
MDCK	EC₅₀	1.5 nM Compound: 5	Antiviral activity against oseltamivir-resistant Influenza A virus A/WSN/1933(H1N1) infected in MDCK cells assessed as protection against virus-induced cytopathic effect after 48 hrs by CellTiter 96 AQueous Non-Radioactive cell proliferation assay Antiviral activity against oseltamivir-resistant Influenza A virus A/WSN/1933(H1N1) infected in MDCK cells assessed as protection against virus-induced cytopathic effect after 48 hrs by CellTiter 96 AQueous Non-Radioactive cell proliferation assay	[PMID: 27167096]
MDCK	IC₅₀	0.2 nM Compound: Peramivir	Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222M mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222M mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase	[PMID: 19651908]
MDCK	IC₅₀	0.2 nM Compound: Peramivir	Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase	[PMID: 19651908]
MDCK	IC₅₀	0.28 nM Compound: peramivir	Antiviral activity against Influenza A virus (A/Washington/01/2007 (H3N2)) measured in MDCK cells by NA inhibition assay Antiviral activity against Influenza A virus (A/Washington/01/2007 (H3N2)) measured in MDCK cells by NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	0.3 nM Compound: Peramivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	[PMID: 19651908]
MDCK	IC₅₀	0.3 nM Compound: Peramivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222V mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222V mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	[PMID: 19651908]
MDCK	IC₅₀	0.3 nM Compound: Peramivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	[PMID: 19651908]
MDCK	IC₅₀	0.3 nM Compound: Peramivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase	[PMID: 19651908]
MDCK	IC₅₀	0.3 nM Compound: Peramivir	Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222V mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222V mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase	[PMID: 19651908]
MDCK	IC₅₀	0.43 nM Compound: peramivir	Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 1 with neuraminidase E119V mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by NA inhibition assay Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 1 with neuraminidase E119V mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	0.5 nM Compound: peramivir	Antiviral activity against Influenza A virus (A/Washington/01/2007 (H3N2)) measured in MDCK cells by fluorescent NA inhibition assay Antiviral activity against Influenza A virus (A/Washington/01/2007 (H3N2)) measured in MDCK cells by fluorescent NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	0.51 nM Compound: peramivir	Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) with neuraminidase E119(V/I) mutant isolated from immunocompromized patient measured after X/CD3 additional passages in MDCK cells by NA inhibition assay Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) with neuraminidase E119(V/I) mutant isolated from immunocompromized patient measured after X/CD3 additional passages in MDCK cells by NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	0.9 nM Compound: peramivir	Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 2 with neuraminidase E119I mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by NA inhibition assay Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 2 with neuraminidase E119I mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	1 nM Compound: Peramivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase D198G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase D198G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase	[PMID: 19651908]
MDCK	IC₅₀	1.47 nM Compound: peramivir	Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 1 with neuraminidase E119V mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by fluorescent NA inhibition assay Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 1 with neuraminidase E119V mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by fluorescent NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	1.72 nM Compound: Peramivir	Antiviral activity against influenza A virus infected in MDCK cells assessed as inhibition of neuraminidase activity by fluorimetric assay Antiviral activity against influenza A virus infected in MDCK cells assessed as inhibition of neuraminidase activity by fluorimetric assay	[PMID: 20713668]
MDCK	IC₅₀	142.4 nM Compound: Peramivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	[PMID: 19651908]
MDCK	IC₅₀	213 nM Compound: Peramivir	Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222V and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222V and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase	[PMID: 19651908]
MDCK	IC₅₀	214.07 nM Compound: peramivir	Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 2 with neuraminidase E119I mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by fluorescent NA inhibition assay Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 2 with neuraminidase E119I mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by fluorescent NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	27 nM Compound: Peramivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase	[PMID: 19651908]
MDCK	IC₅₀	3 nM Compound: Peramivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase	[PMID: 19651908]
MDCK	IC₅₀	3 nM Compound: Peramivir	Antiviral activity against influenza B virus infected in MDCK cells assessed as inhibition of neuraminidase activity by fluorimetric assay Antiviral activity against influenza B virus infected in MDCK cells assessed as inhibition of neuraminidase activity by fluorimetric assay	[PMID: 20713668]
MDCK	IC₅₀	3.51 nM Compound: Peramivir	Antiviral activity against influenza A virus H3N2 infected in MDCK cells assessed as inhibition of neuraminidase activity by fluorimetric assay Antiviral activity against influenza A virus H3N2 infected in MDCK cells assessed as inhibition of neuraminidase activity by fluorimetric assay	[PMID: 20713668]
MDCK	IC₅₀	33.56 nM Compound: peramivir	Antiviral activity against sInfluenza A virus (A/Texas/12/2007 (H3N2)) with neuraminidase E119(V/I) mutant isolated from immunocompromized patient measured after X/CD3 additional passages in MDCK cells by fluorescent NA inhibition assay Antiviral activity against sInfluenza A virus (A/Texas/12/2007 (H3N2)) with neuraminidase E119(V/I) mutant isolated from immunocompromized patient measured after X/CD3 additional passages in MDCK cells by fluorescent NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	43.6 nM Compound: Peramivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	[PMID: 19651908]
MDCK	IC₅₀	562.1 nM Compound: Peramivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222V and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222V and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	[PMID: 19651908]
MDCK	IC₅₀	82.8 nM Compound: Peramivir	Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase	[PMID: 19651908]
MDCK	IC₅₀	891.4 nM Compound: Peramivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	[PMID: 19651908]
MDCK	IC₅₀	9.43 nM Compound: Peramivir	Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of neuraminidase activity by fluorimetric assay Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of neuraminidase activity by fluorimetric assay	[PMID: 20713668]
MDCK	IC₅₀	95.5 nM Compound: Peramivir	Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222M and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222M and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase	[PMID: 19651908]

体外実験

Peramivir (0.3125-40 μM, 4 h) has nontoxicity to macrophage^[1].
Peramivir (2-10 μM, 6-12 h) inhibits cytokine release in LPS-induced hPBMCs^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:	RAW 264.7
Concentration:	0.3125 μM, 0.625 μM, 1.25 μM, 2.5 μM, 5 μM, 10 μM, 20 μM, 40 μM
Incubation Time:	4 h
Result:	Showed no apparent toxicity in the peramivir-treated macrophages at concentrations up to 40 μM.

体内実験

Peramivir (20-60 mg/kg, Intraperitoneal injection, single dose) inhibits LPS-induced cytokine storm, attenuates acute lung injury and prolongs the survival in cytokine storm syndrome model mice^[1].
Peramivir (75 mg/kg, Intramuscular injection, once a day for 7 days) rescued BALB scid mice from lethal challenge with BR/08 in immunocompromised murine models of infuenza B virus infection^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Cytokine storm syndrome model mice ^[1]
Dosage:	20 mg/kg, 60 mg/kg
Administration:	Intraperitoneal injection (i.p.)
Result:	Decreased 8 cytokines including TNF-a, IFN-a, IFN-γ, chemokines (MCP-1), GM-CSF, IL-1β, IL-6 and IL-12. Showed less inflammatory cell infiltrations, mild alveolar thickening and less bleeding points or congestion. Showed significant protective effects to the lung tissues.

Animal Model:	Immunocompromised murine models of infuenza B virus infection^[2]
Dosage:	75 mg/kg
Administration:	Intramuscular injection (i.m.)
Result:	Conferred complete protection against lethality, whether it was administered in one (1×), two (2×), or four (4×) doses, with maximum mean weight loss of 10% to 14%. Resulted in a trend of decreasing virus replication in the nasal cavities and lungs. Reduced the virus titers and replication.

臨床実験

分子量

328.41

分子式

C₁₅H₂₈N₄O₄

CAS 番号

330600-85-6

Appearance

Solid

Color

White to off-white

SMILES

O[C@H]1[C@]([C@H](C(CC)CC)NC(C)=O)([H])[C@H](NC(N)=N)C[C@@H]1C(O)=O

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

1 M HCl : ≥ 100 mg/mL (304.50 mM)

DMSO : < 1 mg/mL (insoluble or slightly soluble)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.0450 mL	15.2249 mL	30.4497 mL
5 mM	0.6090 mL	3.0450 mL	6.0899 mL
10 mM	0.3045 mL	1.5225 mL	3.0450 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

純度とドキュメンテーション

純度: 99.94%

Select Batch:

データシート (286 KB) SDS (396 KB)

COA (259 KB) HNMR (218 KB) RP-HPLC (247 KB) MS (68 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Zhang C, et al. Peramivir, an anti-influenza virus drug, exhibits potential anti-cytokine storm effects [J]. Frontiers in Immunology, 2022, 13: 856327. [Content Brief]

[2]. Pascua P N Q, et al. Pathogenicity and peramivir efficacy in immunocompromised murine models of influenza B virus infection [J]. Scientific reports, 2017, 7(1): 7345. [Content Brief]

[3]. Alame M M, et al.. Peramivir: a novel intravenous neuraminidase inhibitor for treatment of acute influenza infections [J]. Frontiers in microbiology, 2016, 7: 450. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

1 M HCl	1 mM	3.0450 mL	15.2249 mL	30.4497 mL	76.1244 mL
	5 mM	0.6090 mL	3.0450 mL	6.0899 mL	15.2249 mL
	10 mM	0.3045 mL	1.5225 mL	3.0450 mL	7.6124 mL
	15 mM	0.2030 mL	1.0150 mL	2.0300 mL	5.0750 mL
	20 mM	0.1522 mL	0.7612 mL	1.5225 mL	3.8062 mL
	25 mM	0.1218 mL	0.6090 mL	1.2180 mL	3.0450 mL
	30 mM	0.1015 mL	0.5075 mL	1.0150 mL	2.5375 mL
	40 mM	0.0761 mL	0.3806 mL	0.7612 mL	1.9031 mL
	50 mM	0.0609 mL	0.3045 mL	0.6090 mL	1.5225 mL
	60 mM	0.0507 mL	0.2537 mL	0.5075 mL	1.2687 mL
	80 mM	0.0381 mL	0.1903 mL	0.3806 mL	0.9516 mL
	100 mM	0.0304 mL	0.1522 mL	0.3045 mL	0.7612 mL

Peramivir Related Classifications

Inflammation/Immunology Infection

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量		濃度		体積		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）	×	体積 _（開始）	=	濃度 _（終了）	×	体積 _（終了）
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
製品名			カスタマ需要量 *
お名前 *			タイトル
メールアドレス *			電話番号 *
デパートメント			組纖名 *
市区町村			都道府県
国或いは地域 *
必ず会社名を記載ください。個人への返信は行いません。
備考

製品名			Lot #
お名前 *			メールアドレス *
電話番号 *			部門 *
組纖名 *			国或いは地域 *
備考

Peramivir (Synonyms: RWJ-270201; BCX-1812)

カスタマーレビュー

Other Forms of Peramivir:

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

IKK アイソフォーム固有の製品をすべて表示:

JNK アイソフォーム固有の製品をすべて表示:

STAT アイソフォーム固有の製品をすべて表示:

p38 MAPK アイソフォーム固有の製品をすべて表示:

ERK アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Peramivir Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

お名前
メール *

	Sorry, but the email address you supplied was invalid.

Peramivir (Synonyms: RWJ-270201; BCX-1812)

カスタマーレビュー

Other Forms of Peramivir:

Peramivir 関連抗体

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

IKK アイソフォーム固有の製品をすべて表示:

JNK アイソフォーム固有の製品をすべて表示:

STAT アイソフォーム固有の製品をすべて表示:

p38 MAPK アイソフォーム固有の製品をすべて表示:

ERK アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

Peramivir 関連抗体

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Peramivir Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

カスタマーレビュー

Request for HNMR Report

Request for HNMR Report